IP Library › Granted Patent US 10,597,735
Granted Patent B2
US 10,597,735 · App. 15/384,507 · Granted Mar 24, 2020

Antibacterial and plasmid elimination agents

Inventors: Kenneth C Keiler (Boalsburg, PA); Stephen J Benkovic (State College, PA)
Assignee: The Penn State Research Foundation
C12Q1/6897C12N1/20C12N9/0069C12N15/1086C12N15/67C12Q1/66C12Y113/12007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,597,735
App. No.
15/384,507
Granted
Mar 24, 2020
Kind
B2
Abstract

Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vive by the addition of the peptides.

Claims (9)

1. A non-natural nucleic acid construct comprising nucleotide sequence encoding a promoter at a 5′ end of the nucleic acid construct, operably linked to a nucleotide sequence encoding a variant fluorescent protein sequence having no stop codon, which is operably linked to a nucleotide sequence is encoding a tmRNA peptide tag at a 3′ end of the nucleic acid construct.

2. The nucleic acid of claim 1 , wherein the promoter is a constitutive promoter.

3. The nucleic acid of claim 1 , wherein the promoter is an inducible promoter.

4. The nucleic acid of claim 1 , wherein the variant fluorescent protein comprises at least one of green fluorescent protein, red fluorescent protein, blue fluorescent protein, yellow fluorescent protein, or variants thereof.

5. A cell comprising a first nucleic acid comprising nucleotide sequence encoding a promoter at a 5′ end of the nucleic acid, operably linked to a nucleotide sequence encoding a variant fluorescent protein having no stop codon, which is operably linked to a nucleotide sequence encoding a tmRNA peptide tag sequence at a 3′ end of the nucleic acid, wherein the cell comprises a cell selected from the group consisting of: bacterial cell, eukaryotic cell, and archael cell.

6. The cell of claim 5 , further comprising a cyclic-peptide expressing plasmid library which expresses peptides of at least about five amino acids to about twenty amino acids.

7. The cell of claim 5 , wherein a cyclic peptide-expressing plasmid library is generated by randomly substituting at least 50% of nucleic acids coding for cyclic peptides with an NNS sequence, wherein N=A, G, T, or C and S=G or C.

8. The cell of claim 7 , wherein the cyclic peptide comprises any one or more of SEQ ID NO's: 1-15.

9. The cell of claim 5 , wherein the cell further comprises a second nucleic acid comprising a nucleotide sequence encoding a promoter at a 5′ end of the nucleic acid, operably linked to a nucleotide sequence encoding a variant fluorescent protein having no stop codon, which is operably linked to at least one nucleotide sequence encoding a tmRNA targeting sequence at a 3′ end of the nucleic acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2016
From: KEILER, KENNETH C.; BENKOVIC, STEPHEN J.
To: THE PENN STATE RESEARCH FOUNDATION
Reel/Frame 040756/0252 →
Continuity (6)
Division 14136261 · Dec 20, 2013
Continuation 12111096 · Apr 28, 2008
Continuation In Part 11758995 · Jun 6, 2007
Provisional Application 60914129 · Apr 26, 2007
Provisional Application 60811967 · Jun 7, 2006
Related Publication 20170096717A1 · Apr 6, 2017
Cited By (1)
US 12,319,752